Hypertriglyceridemia and Cardiovascular Diseases: Revisited.
10.4070/kcj.2016.46.2.135
- Author:
Seung Hwan HAN
1
;
Stephen J NICHOLLS
;
Ichiro SAKUMA
;
Dong ZHAO
;
Kwang Kon KOH
Author Information
1. Department of Cardiology, Gachon University Gil Medical Center, Incheon, Korea. kwangk@gilhospital.com
- Publication Type:Review
- Keywords:
Residual cardiovascular risk;
Hypertriglyceridemia;
Treatment;
Cardiovascular disease
- MeSH:
Apolipoprotein C-III;
Cardiovascular Diseases*;
Cholesterol;
Cholesterol, HDL;
Epidemiologic Studies;
Fatty Acids, Omega-3;
Fibric Acids;
Hydroxymethylglutaryl-CoA Reductase Inhibitors;
Hypertriglyceridemia*;
Lipoproteins;
Risk Factors;
Triglycerides
- From:Korean Circulation Journal
2016;46(2):135-144
- CountryRepublic of Korea
- Language:English
-
Abstract:
Residual cardiovascular risk and failure of high density lipoprotein cholesterol raising treatment have refocused interest on targeting hypertriglyceridemia. Hypertriglyceridemia, triglyceride-rich lipoproteins, and remnant cholesterol have demonstrated to be important risk factors for cardiovascular disease; this has been demonstrated in experimental, genetic, and epidemiological studies. Fibrates can reduce cardiovascular event rates with or without statins. High dose omega-3 fatty acids continue to be evaluated and new specialized targeting treatment modulating triglyceride pathways, such as inhibition of apolipoprotein C-III and angiopoietin-like proteins, are being tested with regard to their effects on lipid profiles and cardiovascular outcomes. In this review, we will discuss the role of hypertriglyceridemia, triglyceride-rich lipoproteins and remnant cholesterol on cardiovascular disease, and the potential implications for treatment stargeting hypertriglyceridemia.
